US FDA classifies recall of Abiomed's blood pumps as most serious
J&J Agrees to Buy Heart-Device Maker Abiomed for $16.6 Billion
J&J to buy Abiomed in $16.6B deal to boost cardiovascular business
Abiomed Stock Surges on Johnson & Johnson Takeover
Abiomed stock rockets after J&J buyout deal valued at $16.6 billion
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)